Benefiting from strong demand for Cabometyx and Dysport, sales momentum accelerated for Ipsen in Q1 21. Importantly, Cabometyx, in combination with Opdivo, has been approved as a first-line of treatment for renal cell carcinoma, and this is quite encouraging. Although the phased launch of Somatuline’s generic (expected by mid-2021) is a key risk, management reiterated its FY21 guidance.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Decent start to the year
Benefiting from strong demand for Cabometyx and Dysport, sales momentum accelerated for Ipsen in Q1 21. Importantly, Cabometyx, in combination with Opdivo, has been approved as a first-line of treatment for renal cell carcinoma, and this is quite encouraging. Although the phased launch of Somatuline’s generic (expected by mid-2021) is a key risk, management reiterated its FY21 guidance.